Literature DB >> 23625324

[Anticoagulation].

B Pötzsch1.   

Abstract

Anticoagulant drugs belong to the group of antithrombotic agents and are successfully used in the prophylaxis and treatment of thromboembolic disorders. The use of anticoagulants in the prevention of deep venous thrombosis has significantly lowered the risk of venous thrombosis and fatal pulmonary embolisms even in high-risk situations such as orthopedic surgery. Anticoagulants play a central role in the treatment of acute venous thrombosis and in the prevention of recurrent events. Long-term anticoagulation therapy with orally active anticoagulants significantly reduces the risk of thromboembolic complications in patients showing cardiac arrhythmias. Whereas a few years ago heparins and vitamin K antagonists were the dominant anticoagulants, today a wide range of anticoagulants with improved pharmacological profiles are available. It remains an open question whether these new anticoagulants will improve the efficacy, safety, and acceptance of anticoagulant treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625324     DOI: 10.1007/s00063-013-0243-1

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  16 in total

1.  Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity.

Authors:  F Depasse; G T Gerotziafas; J Busson; P Van Dreden; M M Samama
Journal:  J Thromb Haemost       Date:  2004-02       Impact factor: 5.824

Review 2.  Direct thrombin inhibitors in cardiovascular disease.

Authors:  Kyle A Arsenault; Jack Hirsh; Richard P Whitlock; John W Eikelboom
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

Review 3.  Advances in the management of venous thromboembolism.

Authors:  Sam Schulman
Journal:  Best Pract Res Clin Haematol       Date:  2012-08-02       Impact factor: 3.020

Review 4.  Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.

Authors:  A C Spyropoulos; J D Douketis; G Gerotziafas; S Kaatz; T L Ortel; S Schulman
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

Review 5.  Valvular heart disease and pregnancy.

Authors:  Thomas A Traill
Journal:  Cardiol Clin       Date:  2012-05-30       Impact factor: 2.213

Review 6.  Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Authors:  Bengt I Eriksson; Daniel J Quinlan; Jeffrey I Weitz
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes.

Authors:  D N Mohr; M D Silverstein; D M Ilstrup; J A Heit; B F Morrey
Journal:  Mayo Clin Proc       Date:  1992-09       Impact factor: 7.616

View more
  5 in total

1.  Computational design, functional analysis and antigenic epitope estimation of a novel hybrid of 12 peptides of hirudin and reteplase.

Authors:  Yingting Cai; Jingxiao Bao; Xingzhen Lao; Heng Zheng; Jianhua Chen; Rong Yu
Journal:  J Mol Model       Date:  2015-08-13       Impact factor: 1.810

2.  [Bedside implantation of a new temporary vena cava inferior filter : German results from the European ANGEL registry].

Authors:  S Baumann; T Becher; K Giannakopoulos; C Jabbour; C Fastner; I El-Battrawy; U Ansari; D Lossnitzer; M Behnes; A Alonso; T Kirschning; R Dissmann; O Kueck; D Stern; G Michels; M Borggrefe; I Akin
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05-03       Impact factor: 0.840

Review 3.  [Cardiovascular pharmacotherapy. Risks and adverse effects].

Authors:  N Voigt; J Heijman; D Dobrev
Journal:  Herz       Date:  2014-03       Impact factor: 1.443

Review 4.  Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.

Authors:  Klaus Grossmann
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

5.  Anticoagulants for Treatment of Alzheimer's Disease.

Authors:  Klaus Grossmann
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.